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Abstract
Dopamine receptors are implicated in the pathogenesis and treatment of nearly every 
neuropsychiatric disorder. Although thousands of drugs interact with these receptors, our 
molecular understanding of dopaminergic drug selectivity and design remains clouded. To 
illuminate dopamine receptor structure, function, and ligand recognition, we determined crystal 
structures of the D4 dopamine receptor in its inactive state bound to the antipsychotic drug 
nemonapride, with resolutions up to 1.95 angstroms. These structures suggest a mechanism for the 
control of constitutive signaling, and their unusually high resolution enabled a structure-based 
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campaign for new agonists of the D4 dopamine receptor. The ability to efficiently exploit structure 
for specific probe discovery-rapidly moving from elucidating receptor structure to discovering 
previously unrecognized, selective agonists-testifies to the power of structure-based approaches.
Dopamine (DA) receptors are G protein-coupled receptors (GPCRs) that are major 
therapeutic targets for schizophrenia, Parkinson’s Disease, drug abuse, and impaired 
cognition(1). DA receptors are divided into two subfamilies: the Gαs/off-coupled D1-like 
family (e.g. D1 and D5 dopamine receptors) and the Gαi/o-coupled D2-like family (e.g. D2, 
D3, and D4 dopamine receptors [DRD2, DRD3 and DRD4])(2). As DRD4 has been 
implicated in many disorders including attention deficit disorder, metastatic progression and 
penile erection, DRD4-selective drugs have therapeutic promise(2). Further, although 
>10,000 drugs and drug-like compounds have been reported to have DA receptor activity 
(data set S1), our understanding of the molecular mechanisms for DA receptor selectivity 
and activity is incomplete, as only one relatively low resolution structure--the DRD3--has 
been reported(3).
To obtain well-ordered crystals for high resolution studies of the human DRD4 in complex 
with nemonapride, we replaced residues 228–336 of intracellular loop 3 (ICL3) with 
thermostabilized apocytochrome b562RIL (BRIL) (4) yielding DRD4-BRIL--which has a 
binding affinity for 3H-N-methylspiperone similar to native DRD4 (Table S2). The DRD4/
nemonapride complex crystals diffracted to 1.95 Å resolution (Fig. S1, S2 and Table S1) 
revealing a full network of water molecules and ions (Fig. 1A). The most dramatic structural 
differences between the DRD3 (PDB ID: 3PBL) and DRD4 structures are in ECL3, the 
cytoplasmic ends of TM VI and VII, and the intracellular ends of TM III and V (Fig. S3). 
Compared to DRD3, TM VI and VII in DRD4 are further apart, with the cytoplasmic tip of 
TM VI located approximately 2Å closer to TM V (Fig. S3).
The position of DRD3’s TM VI appears fixed by an inter-helical hydrogen bond between 
Y3657.35 and H3496.55, whereas in DRD4 this is absent as V4307.35 cannot hydrogen bond 
with H4146.55 (Fig. S3). Given the critical nature of TMs V and VI in GPCR activation (5), 
we wondered if this apparent constraint in DRD3 versus DRD4 has functional 
consequences. A V4307.35Y mutation in DRD4 which recapitulates DRD3’s inter-helical 
hydrogen bond increases DRD4 constitutive activity (Fig. S4A). The reverse mutation in 
DRD3 (Y3657.35V), which mimics DRD4 configuration, diminishes DRD3 constitutive 
activity (Fig. S4B). Thus, the hydrogen bond between 7.35 and 6.55 potentiates DRD3 
constitutive activity, while its absence in DRD4, together with the closer proximity of TM V 
and VI, may explain the more inactive DRD4/nemonapride structure. Meanwhile, H6.55 
occupies different rotamer states in DRD4 and DRD3, which could lead to differential 
ligand binding and activity between the two subtypes, as H6.55 forms a direct hydrogen bond 
with eticlopride in DRD3 (3), while H6.55 forms water mediated contacts with nemonapride 
in DRD4 (Fig. 1, B and C).
High-resolution structures of the A2A adenosine (A2AAR) (Fig. 2A)(6), δ-opioid (δ-OR) 
(Fig. 2A)(7), β1-adrenergic (β1AR)(8), and protease-activated (PAR1)(9) receptors revealed 
a conserved Na+/water cluster, coordinated by two highly conserved residues, D2.50 and 
S3.39 (10). Here we determined structures of the DRD4/nemonapride complex in the 
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presence and absence of ~200 mM added sodium and observe an electron density for sodium 
only when it was added during crystallization (Fig. 2A and S5). This provides the first direct 
structural evidence for the presence of a sodium ion in its binding site [see (10) for 
discussion]. Importantly, the DRD4 construct used for crystallization displays similar 
sodium-dependent allosteric regulation as the wildtype (Fig. S6A). Similar to A2AAR and δ-
OR, sodium forms a salt bridge with D802.50 and makes polar interactions with S1223.39 and 
two water molecules in DRD4 (Fig. 2A). A previously described third coordinating water 
was not observed, likely due to the lower resolution of 2.15 Å (Fig. 2A); the β1AR 2.1 Å 
structure also shows weaker density for this water molecule compared to structures of δ-OR 
and A2AAR (8). Compared with other tested GPCRs, the DRD4 has lower sodium affinity 
than δ-OR, μ-OR or A2AAR (Fig. 2B–E and S6A–C). As expected (7), lowering [Na+] 
potentiates DRD4 constitutive activity in a nemonapride-sensitive fashion (Fig. S7).
The sodium pocket in DRD4 adopts nearly identical conformations in the sodium-bound and 
sodium-free states (rmsd of 0.084 Å, calculated over D802.50, L1183.35, S1223.39, and four 
water molecules) (Fig. 2A). Consistent with this finding, MD simulations of the inactive 
state show that the sodium-free pocket does not collapse even when nemonapride is absent 
(Fig. S8). Instead, the pocket fills with water and D802.50 and S1223.39 become more 
mobile, though their average positions remain similar to those observed with sodium bound 
(Fig. S8). MD simulations also predict that sodium’s position and mobility is affected by 
nemonapride (Fig. S9A). With nemonapride bound, sodium mostly occupies a cluster of 
positions surrounding its crystallographic pose, but occasionally binds a second cluster about 
2.5 Å closer to nemonapride, as observed in other GPCRs (11, 12). In simulations of 
nemonapride-free DRD4, sodium transitioned more frequently between clusters and spent 
more time in the second cluster, occasionally even occupying the now empty ligand binding 
site (Fig. S9A, S10 and S11). In both clusters, coordination to D802.50 and S1223.39 was 
largely maintained, with the side-chain hydroxy of S1223.39 rotating towards sodium. 
Interestingly, simulations also indicate that nemonapride’s binding pose is more stable in the 
presence of sodium (Fg. S9B), in agreement with the higher affinity of nemonapride-like 
ligands in the presence of sodium(13, 14).
Nemonapride interacts with the conserved aspartate D1153.32, while it’s benzamide ring 
binds within a conserved orthosteric binding pocket (OBP) lined by residues from TM II, III, 
V, VI, VII, and ECL2.(Fig. 1, B and C). Nemonapride’s conformation is constrained by an 
intra-molecular hydrogen bond between its amide nitrogen and the methoxy substituent of 
the benzyl ring. Nemonapride’s methoxy ring is fixed by inter-molecular contacts with side 
chains of the conserved residues F4116.52 and V1163.33, and by a hydrogen bond with the 
sidechain of S1965.42 (Fig. 1C).
Nemonapride’s unsubstituted benzyl group interacts with non-conserved residues V872.57, 
L902.60, F912.61 and L1113.28, all of which have been implicated by mutagenesis for 
specifying DRD4 pharmacology (15, 16). In the DRD4 structure, these residues emerge as 
part of a new extended binding pocket (EBP) bordered by TM II and TM III residues (Fig. 1, 
B and C), distinct from that reported for DRD3 [(3, 17, 18); see Fig. 1D]. This DRD4 EBP: 
(1) reaches deep into the adjacent position between TM II and TM III (Fig. 1, D and E); and 
(2) is poorly conserved among the closely related members of the D2-like subfamily (Fig. 
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S12). These differences combine to sculpt the distinctive shapes and sizes of the DRD4 and 
DRD3 EBPs (Fig. 1D), at the core of which is a crevice formed by residues 2.61 and 3.28. In 
DRD4, nemonapride’s unsubstituted benzyl group is wedged between F912.61 and L1113.28, 
indicating that its binding to DRD3 likely requires structural rearrangements to avoid clashes 
with V862.61 and F1063.28 (Fig. 1E).
Docking DRD4-selective ligands against the DRD4/nemonapride structure revealed that 
their aryl rings docked into the EBP, connecting directly and rigidly to the aminergic 
heterocycles of the antagonists, unlike nemonapride which is nonselective. As docking 
forces these rings into contact with specificity residues 2.61 and 3.28 (Fig. S13), we 
hypothesized that steric clashes with F3.28, and lack of interactions with V2.61 in DRD3 and 
DRD2, contribute to DRD4-selectivity. Introducing a F2.61V/L3.28F double substitution in 
DRD4 to mimic the DRD2 and DRD3 configuration attenuates affinities of DRD4-selective 
compounds, with non-selective compounds relatively unaffected (Table S2, S4 and S6). 
Introduction of the reverse double mutant into DRD2 (V2.61F/F3.28L) increased the affinity 
for DRD4-selective ligands without altering the affinities of non-selective compounds (Table 
S3, S5 and S7), providing an atomic resolution model of DRD4 ligand selectivity (Fig. 1E 
and S13).
The structural definition of the EBP afforded us the opportunity to seek new DRD4 selective 
agonists with potentially novel properties, including biased agonism. Accordingly, we 
docked a library of over 600,000 cationic, “lead-like”(19) molecules from ZINC(20) (http://
zinc15.docking.org) against the 1.95 Å DRD4 structure, seeking molecules that bound in 
both the OBP and EBP (Fig. 3A and METHODS). Of the ten high-ranking molecules tested 
(Fig. 3B and Table S8) with 3 and 9 being sub-μM agonists with 9 being DRD4 selective 
(Table S11). Both 3 and 9 are topologically dissimilar to dopaminergic ligands cataloged in 
ChEMBL20 (21), with the closest dopaminergic analog to 9, for instance, having a Tc of 
0.27, suggesting they represent new dopaminergic scaffolds (Table S11). While 3 and 9 are 
dissimilar from one another, they share a motif where the central aminergic nitrogen is 
separated by two carbons from a hydrogen-donating amine which makes a bifurcated 
hydrogen-bond to Asp1153.32 (Fig. 3, C and D).
Seventy-five analogs of 9 were next docked with 15 prioritized for testing based on docking 
score, EBP occupancy, interaction with Leu187ECL2, and chemical diversity (table S9). All 
retained the quinolone and aminergic moieties, which engage key residues of the OBP, with 
most variations in the side chain predicted to interact with EBP residues. For example, 9–6 
and 9–11 (Fig. 4A and Table S11) retain the quinolone heterocycle and the bidentate amino 
groups, with the hydroxymethyl replaced by simple extended side chains to flexibility and 
deleting a potential competing internal hydrogen bonding group for the aminergic amine. 
While retaining major interactions of the quinolone heterocycle with the OBP, the increased 
flexibility of these analogs facilitated better packing against the specificity determining EBP 
of DRD4 (Fig. 4B and S14A). 9–6 and 9–11 displayed a 20-fold improvement over 9 with 
no activity at DRD2 or DRD3 at 10 μM (Fig. 4A, 4B, S14A and Table S11). They are potent 
DRD4 partial agonists (Fig. 4D and S14B) with arrestin bias factors of 20- and 7.8-fold 
relative to quinpirole (Fig. 4D and S14B). This bias is consistent with the docking, which 
selected for interactions not only with the EBP but also with predicted arrestin bias-
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associated Leu187ECL2(22) with which the conserved quinolone interacts (Fig. 4B and 
S14A). EBP residue mutations disrupt the affinities of the new agonists (Table S11), 
consistent with their docked poses (Fig. 4B and S14A).
To improve compound potency and specificity we docked 169 analogs of 9–6 and 9–11 with 
alternate interactions in the EBP (table S10). We explored many linkers, including those that 
increased and decreased polarity, flexibility or rigidity, and conservative substitutions off the 
quinolone ring; ultimately 27 well-fitting, diverse analogs were assayed (Table S10). The 
most potent were 9-6-23 and 9-6-24 that featured a “right hand side” linker extended to four 
atoms, the last of being a phenolic ether oxygen. This oxygen, which allows for an internal 
hydrogen bond to the aminergic amine of the molecule, positions the distal aryl ring over the 
EBP-defining F912.61 (Fig. 4C). 9-6-23 and 9-6-24 had Ki values of 30 and 3 nM at DRD4, 
respectively, without measurable affinity for either DRD2, DRD3 or the EBP DRD4 mutant 
F2.61V / L3.28F, thereby increasing selectivity to >3300-fold (Table S10 and S11). 9-6-24 
was a DRD4 partial agonist with a 7.4-fold bias toward arrestin over Gαi/o signaling, 
referenced to quinpirole (Fig. 4E). In counter-screens, neither the parent compound 9-6 nor 
9-6-24 had substantial agonist activity against 320 non-olfactory GPCRs (Fig. 4, F and G). 
The selectivity of 9-6-24 places it among the most potent and specific DRD4 agonists 
characterized. Meanwhile, 9-6-24’s arrestin bias contrasts with that of earlier agonists, 
which are either balanced or slightly G protein biased (Fig. S15). Accordingly, we are 
making 9-6-24 openly available to the community to use as probe for DRD4 function as 
UCSF924 (below).
Here a combination of high resolution structure determination, computational, and 
biochemical studies has illuminated the structure and function of the DRD4 at atomic 
resolution. The leveraging of the DRD4 structure for potent and selective ligand discovery—
with such discovery occurring contemporaneously with structure determination and 
functional exploration—attests to the pragmatism of the GPCR structural program for probe 
and therapeutic lead development.
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Fig. 1. Human D4 –nemonapride complex
A, Overview of the DRD4-nemonapride complex structure with water molecules depicted as 
red spheres. B, Conformation of the binding pocket with nemonapride shown by sticks with 
magenta carbons. The protein is displayed in cartoon representation, with the 11 contact 
residues within 4.0 Å from the ligand shown by slate blue sticks. Structured water molecules 
are shown as red spheres. Ballesteros–Weinstein numbering is shown as superscript. C, 
Diagram of ligand interactions in the binding pocket side chains at 4.0 Å cut-off. Hydrogen 
bonds are shown in dashed lines. D, Side views of the sliced binding pocket in DRD4-
nemonapride and DRD3-eticlopride complex. The pocket surfaces are colored gray. Ligands 
are shown as capped sticks with carbons colored magenta (Nemonapride) and orange 
(eticlopride). E, the different position of phenylalanine in DRD4 (slate blue) and DRD3 
(green). Ligands are colored as in panel D.
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Fig. 2. Structural and functional details of the DRD4’s allosteric Na+ site
A, Close ups of A2A adenosine receptor (magenta), δ-OR receptor (green), D4 dopamine 
receptor without sodium (slate blue) and D4 dopamine receptor with sodium (slate blue) 
respective Na+ allosteric pockets are shown as inserts. The receptors are shown as a ribbon, 
and residues lining the Na+ cavity are shown as sticks and labeled according to Ballesteros-
Weinstein scheme. Water molecules in the cluster are shown as red spheres. Na+ is displayed 
as yellow spheres. The salt bridge between Na+ and D2.50 and hydrogen bonds are shown as 
grey dotted lines. B, C, D, E, The allosteric effect of graded dose of sodium on DAMGO, 
DADLE, NECA or dopamine affinity were respectively measured at μ-OR (B), δ-OR (C), 
A2AAR (D) and DRD4 (E).
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Fig. 3. Discovery of a new DRD4 selective agonist
A, Structure-based strategy for discovery of novel DRD4 chemotypes from docking screens 
against large virtual libraries. B, Single-point competition binding assay of 10 candidate 
molecules against the DRD4 antagonist 3H-N-Methylspiperone. Each ligand was tested at 5 
μM and for those with > 50% inhibition affinity was calculated in full displacement curves; 
data represent mean ± s.e.m. (n = 3 measurements). C, D Docking poses of compounds 3 
(C) and 9 (D), new DRD4 agonists. The D4 dopamine receptor and residues are shown in 
tan. Compounds are shown as capped sticks with carbons colored cyan (compound 3) and 
green (compound 9). Ballesteros–Weinstein numbering is shown as superscript.
Wang et al. Page 9
Science. Author manuscript; available in PMC 2018 April 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 4. Structure-guided optimization of potent DRD4 agonists
A, Overview of structure-guided analog-by-catalog optimization towards compound 9-6-24 
(see main text for details). B, C, Docking poses of compounds 9-6 (B) and 9-6-24 (C). Both 
optimized analogs have a simplified right hand linker while maintaining key interactions and 
occupying the EBP. The D4 dopamine receptor and residues are shown in tan. Compounds 
are shown as capped sticks with carbons colored pink (compound 9-6) and green (compound 
9-6-24). Ballesteros–Weinstein numbering is shown as superscript. D, E, Normalized 
concentration-response studies for compound 9-6 (D) and 9-6-24 (E) at human cloned 
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DRD4–mediated activation of Gαi/o and arrestin translocation. Error bars in (D) and (E) 
denote SEM from a minimum of three assays. See METHODS for details on bias factor 
calculation. F, G, Compound 9-6 (F) and Compound 9-6-24 (G) were screened against 320 
non-olfactory GPCRs for agonism in the arrestin recruitment TANGO assay. Each point 
shows luminescence normalized to basal level at a given GPCR, with vertical lines 
indicating the standard error of the mean.
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